
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus is supported by a compelling BOT+BAL neoadjuvant thesis, where peer-reviewed NEST and UNICORN data showed roughly 30% pCR in MSS disease versus a much lower benchmark the ROBBIN study is powered to detect, while the FDA-agreed design could also spare about a third of the experimental arm from oxaliplatin if pCR trends hold. The balance sheet has improved materially, with about $86.9M of cash at 9/30 and runway through 3Q27, plus up to about $255M in milestone-linked warrant value, reducing near-term financing risk as 3Q revenue of $31.5M exceeded expectations and operating cash use fell to $20.1M. Its first marketing authorizations in Armenia and expanding access revenue in Europe and the Americas validate commercial traction outside the U.S., while ROBBIN’s 1Q27 first patient and 4Q27 pathologic-response interim create clear catalysts for value re-rating.
Bears say
Agenus is a high-risk, pre-commercial biotech whose value hinges on whether botensilimab plus balstilimab can prove a clinically meaningful event-free survival benefit in the planned ~850-patient ROBBIN study, since encouraging Phase I/II pathologic responses and ctDNA clearance have not yet been validated in a randomized registrational setting. The company also faces substantial regulatory and competitive pressure in the crowded MSS colorectal cancer space, where FDA approval, reimbursement, and market penetration remain uncertain even if interim data are positive. Financially, $86.9M of cash, cash equivalents, and short-term investments at 9/30/26 appears only to support operations through 3Q27 absent warrant exercise, while reliance on a possible ~$255M from milestone-linked warrants creates material dilution and refinancing risk if timelines slip.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Agenus (AGEN) Forecast
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares